XenoPort reports positive trial data By: MarketMinute » Stock News September 15, 2015 at 11:42 AM EDT XenoPort Inc. (Nasdaq: XNPT) reported positive results from a Phase 2 clinical trial of its psoriasis treatment XP23829 but the stock price tumbled $1.89 to close at $4.84.
